Allogene Therapeutics Announces September 2019 Investor Conference Schedule
03 September 2019 - 10:30PM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) therapies for cancer, today announced that
management plans to present at the Morgan Stanley 17th Annual
Global Healthcare Conference.
Monday, September 9, 20191:05 p.m. ETNew York, NY
The webcast will be made available on the Company's website
at www.allogene.com under the Investors tab in the News and
Events section. Following the live audio webcast, a replay will be
available on the Company's website for approximately 30 days.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the
development of allogeneic chimeric antigen receptor T cell
(AlloCAR T™) therapies for cancer. Led by a world-class management
team with significant experience in cell therapy, Allogene is
developing a pipeline of “off-the-shelf” CAR T cell
therapy candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and
at greater scale to more patients. For more information,
please visit www.allogene.com, and follow @AllogeneTx on
Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the ability to develop allogeneic
CAR T therapies for cancer and the potential benefits of AlloCAR T
therapy. Various factors may cause differences between Allogene’s
expectations and actual results as discussed in greater detail in
Allogene’s filings with the Securities and Exchange Commission
(SEC), including without limitation in its Form 10-Q for the
quarter ended June 30, 2019. Any forward-looking statements that
are made in this press release speak only as of the date of this
press release. Allogene assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Apr 2024 to May 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From May 2023 to May 2024